Drug Profile
Luxeptinib - Aptose Biosciences/CrystalGenomics
Alternative Names: CG-026806; CG-806Latest Information Update: 06 Apr 2023
Price :
$50
*
At a glance
- Originator CrystalGenomics
- Developer Aptose Biosciences; CrystalGenomics
- Class Antineoplastics; Fluorobenzenes; Imidazoles; Isoindoles; Phenylurea compounds; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Apoptosis stimulants; Aurora kinase inhibitors; Discoidin domain receptor 2 antagonists; Extracellular signal-regulated MAP kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Interleukin 6 inhibitors; Lyn protein-tyrosine kinase inhibitors; NLRP3 protein inhibitors; Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-akt inhibitors; Src-Family kinase inhibitors; Syk kinase inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Preclinical Mantle-cell lymphoma
- No development reported Haematological malignancies
Most Recent Events
- 05 Apr 2023 Aptose Biosciences has patent protection for compounds including CG 806, pharmaceutical compositions comprising CG 806, and methods of their use for treating various diseases in USA and Europe
- 10 Dec 2022 Efficacy, pharmacokinetic and adverse events data from phase Ia/Ib trial in Chronic lymphocytic leukaemia and Non-Hodgkin's lymphoma presented at 64th American Society of Hematology Annual Meeting and Exposition
- 10 Dec 2022 Efficacy, adverse events and pharmacokinetics data from a phase Ia/b trial in Acute myeloid leukemia presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-2022)